| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2002 | WO2001093890B1 Botulinum toxin implant |
| 05/10/2002 | WO2001093827B1 Neurotoxin implant |
| 05/10/2002 | WO2001089498A3 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS |
| 05/10/2002 | WO2001088116A3 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 05/10/2002 | WO2001085201A3 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 05/10/2002 | WO2001085143A3 Pharmaceutical compositions for transdermal administration of anti-inflammatory agents |
| 05/10/2002 | WO2001082919A3 Methods of and compounds for inhibiting calpains |
| 05/10/2002 | WO2001081342A3 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
| 05/10/2002 | WO2001079469A3 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| 05/10/2002 | WO2001078710A3 Paclitaxel treatment regimen for metastatic melanoma |
| 05/10/2002 | WO2001076570A3 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses |
| 05/10/2002 | WO2001074329A3 Sustained release beadlets containing stavudine |
| 05/10/2002 | WO2001072288A3 Use of cdp-choline for the treatment of alcohol withdrawal syndrome |
| 05/10/2002 | WO2001070808A3 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 05/10/2002 | WO2001070706A3 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents |
| 05/10/2002 | WO2001070207A3 5ht2 agonists for controlling iop and treating glaucoma |
| 05/10/2002 | WO2001068697A3 Methods and compositions for immunoregulation |
| 05/10/2002 | WO2001068135A3 Compositions and methods for affecting osteogenesis |
| 05/10/2002 | WO2001068063A3 Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| 05/10/2002 | WO2001068034B1 1, 2, 4-triazoloribonucleoside prodrugs and their administration to treat viral disease conditions |
| 05/10/2002 | WO2001064650A3 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 05/10/2002 | WO2001064251A3 Combination chemotherapy |
| 05/10/2002 | WO2001064236A3 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 05/10/2002 | WO2001064214A3 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 05/10/2002 | WO2001049281A3 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
| 05/10/2002 | WO2001048190A3 Therapeutic uses of lna-modified oligonucleotides |
| 05/10/2002 | WO2001046455A3 Survivin promotion of angiogenesis |
| 05/10/2002 | WO2001046420A3 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof |
| 05/10/2002 | WO2001043733A3 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
| 05/10/2002 | WO2001042472A3 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE |
| 05/10/2002 | WO2001041780A3 Use of an immunosuppressant for increasing an antifugal activity of a lipopeptide |
| 05/10/2002 | WO2001041768A3 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 05/10/2002 | WO2001039765A3 Compositions and methods for the induction and treatment of retinal detachments |
| 05/10/2002 | WO2001038326A3 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/10/2002 | WO2001038324A3 Imidazole derivatives and their use as raf kinase inhibitors |
| 05/10/2002 | WO2001036618A3 Transgenic mammals into which a period 1 promoter that confers rhythmical expression has been introduced |
| 05/10/2002 | WO2001036432A3 18 human secreted proteins |
| 05/10/2002 | WO2001034600A9 Protease inhibitors |
| 05/10/2002 | WO2001034599A9 Protease inhibitors |
| 05/10/2002 | WO2001034157A9 Protease inhibitors |
| 05/10/2002 | WO2001034131A3 Combination chemotherapy |
| 05/10/2002 | WO2001034124A3 Use of 5ht-1a-serotonine receptor agonists for treating genetic or functional rhythm disorders in the respiratory system |
| 05/10/2002 | WO2001034117A9 A method for chemoprevention of prostate cancer |
| 05/10/2002 | WO2001032650A3 Alkaline salts of n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide, possess for their preparation, and pharmaceutical composition based on these salts |
| 05/10/2002 | WO2001032155A3 Use of egfr tyrosine kinase inhibitors for treating breast cancer |
| 05/10/2002 | WO2001030332A3 Methods of protecting neuronal function |
| 05/10/2002 | WO2001029036A3 Allosteric sites on muscarinic receptors |
| 05/10/2002 | WO2001028580A3 Modulation of angiogenesis |
| 05/10/2002 | WO2001028545A3 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 05/10/2002 | WO2001028522A3 Method for producing liposome preparation |
| 05/10/2002 | WO2001027135A3 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 05/10/2002 | WO2001026642A3 Methods and compositions for treating neurobehavioral disorders |
| 05/10/2002 | WO2001026629A3 Neutral-cationic lipid for nucleic acid and drug delivery |
| 05/10/2002 | WO2001026618A3 Composition, especially a cosmetic composition, containing a steroid and a liposoluble uv filter |
| 05/10/2002 | WO2001025271A3 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 05/10/2002 | WO2001024784A3 New use |
| 05/10/2002 | WO2001023389A3 Certain alkylene diamine-substituted heterocycles |
| 05/10/2002 | WO2001023386A3 Benzodiazepin derivatives, the production and use thereof |
| 05/10/2002 | WO2001005388A3 Use of a fatty derivative for the treatment of external secretiondisorders |
| 05/10/2002 | WO2001003681A3 Use of flavones, coumarins and related compounds to treat infections |
| 05/10/2002 | WO2001000246A3 Hydrogels derived from chitosan and poly(ethylene glycol) |
| 05/10/2002 | WO2001000186A3 New use of 1,2,4-triazolo'1,5-a! pyrimidines |
| 05/10/2002 | WO2000073507A3 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders |
| 05/10/2002 | WO2000071106A3 Method of treating weight gain |
| 05/10/2002 | WO2000067736A3 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone |
| 05/10/2002 | WO2000058339A3 50 human secreted proteins |
| 05/10/2002 | WO2000053603A9 2-hydroxy methylcyclopro pylidenemethyl purines and -pyrimidines as antiviral agents |
| 05/10/2002 | WO2000053174A9 Modulation of protein expression using carbocyclic aryl alkenoic acid derivatives |
| 05/10/2002 | CA2439382A1 Pharmaceutical or dietary composition containing a vegetable oil, in particular olive oil, and sitosterol |
| 05/10/2002 | CA2431641A1 Treatment of motor fluctuations |
| 05/10/2002 | CA2428012A1 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders |
| 05/10/2002 | CA2427795A1 Sustained release device for treating conditions of the joint |
| 05/10/2002 | CA2427744A1 Anti-inflammatory and healing medicine based on laminarin sulphate |
| 05/10/2002 | CA2427629A1 Gene regulation therapy involving ferritin |
| 05/10/2002 | CA2427613A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 05/10/2002 | CA2427589A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 05/10/2002 | CA2427568A1 Tricyclic derivatives of indole with antiangiogenic activity |
| 05/10/2002 | CA2427565A1 Bis-heterocyclic compounds with antitumour and chemosensitising activity |
| 05/10/2002 | CA2427557A1 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | CA2427394A1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 05/10/2002 | CA2426977A1 Sulphonamides for the treatment of central nervous system diseases |
| 05/10/2002 | CA2426894A1 Method of treating and preventing migraine headaches |
| 05/10/2002 | CA2426815A1 Phase transfer catalyzed glycosidation of an indolocarbazole |
| 05/10/2002 | CA2426762A1 Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
| 05/10/2002 | CA2426658A1 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 05/10/2002 | CA2426395A1 Crystalline forms of fluvastatin sodium |
| 05/10/2002 | CA2426047A1 Therapeutic oligonucleotides of reduced toxicity |
| 05/10/2002 | CA2426026A1 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation |
| 05/10/2002 | CA2426012A1 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane-associating elements |
| 05/10/2002 | CA2425583A1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 05/10/2002 | CA2425286A1 Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis |
| 05/10/2002 | CA2425285A1 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis |
| 05/10/2002 | CA2425067A1 Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
| 05/10/2002 | CA2421705A1 New treatments for restless legs syndrome |
| 05/09/2002 | WO2002036591A2 Inhalative solution formulation containing a tiotropium salt |
| 05/09/2002 | US20020056144 Transgenic animal models for cardiac hypertrophy and methods of use thereof (screening) |
| 05/09/2002 | US20020055666 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| 05/09/2002 | US20020055644 Xanthone analogs for treating infectious diseases and complexation of heme and porphyrins |
| 05/09/2002 | US20020055643 Tubulin binding ligands and corresponding prodrug constructs |
| 05/09/2002 | US20020055636 Pyrroloquinolones as antiviral agents |